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In case we needed reminding, age-related neurodegenerative diseases such as Alzheimer’s disease 
(AD), Parkinson’s disease (PD), and motor neurone disease (MND) have two factors in common: 
(i) advancing age as the single biggest risk factor and (ii) the fact that they are characterized by 
neuronal degeneration. A recent article (1) encourages us to focus on some of the similarities of 
these diseases by demonstrating that features characteristically associated with AD are also com-
monly found in MND.
In their study (1), the group measured key biomarkers of the amyloid cascade [amyloid precursor 
protein (APP), transactive response DNA-binding protein 43 (TDP-43), phosphorylated TDP-43 
(pho-TDP43), amyloid-beta peptide (Aβ), and amyloid precursor protein-binding protein family 
B (Fe 65)] immunohistochemically in postmortem samples of the hippocampus of amyotrophic 
lateral sclerosis (ALS) and ALS–frontotemporal dementia patients. Compared to controls, they 
report increased levels of APP and Aβ peptide in MND patients; the latter change also correlating 
with cytoplasmic pho-TDP-43 expression. In addition, they found decreased Fe65 expression and 
increased expression of pho-tau. Interestingly, these molecular alterations were similar for both ALS 
and ALS–FTD, albeit more pronounced in the latter group. This indicates that the “amyloid cascade,” 
resulting in the accumulation of amyloid β, is activated in the hippocampus of patients with ALS and 
ALS–FTD, and that such activation correlates with alterations in TDP-43.
This is an important finding, because it adds to the growing body of evidence that age-related 
neurodegenerative diseases, rather than being discrete entities, may in fact be different points on 
a continuum, and the corollary of this is that they may all have similar underlying mechanisms. 
Indeed, a brief survey of three age-related neurodegenerative diseases (AD, PD, and MND) reveals 
that there is much overlap in the features associated with these conditions (Table 1), and that they 
have more in common than anything else (Figure 1).
The paper by Gomez-Pinedo et al. (1) is a timely reminder that researchers should perhaps not get 
tied up with the details of these individual diseases that are so important for differential diagnoses. 
Instead, those seeking to illuminate basic underlying mechanisms might do well to pool data for 
FIGUre 1 | Venn diagram summarizing overlap of features associated 
with alzheimer’s disease (aD), Parkinson’s disease (PD), and motor 
neurone disease (mnD).
taBle 1 | typical and associated features of alzheimer’s disease (aD), 
Parkinson’s disease (PD), and motor neurone disease (mnD).
Condition typical features associated features
AD  1.  Aβ deposition (amyloid plaques), 
intraneuronal aggregation of pho-tau
 9.  Movement 
disorder
 2.  Increased amyloid precursor protein 
(APP), accumulation of Aβ and pho-tau
 3. Cholinergic dysfunction
 4. Cognitive changes
 5. Sustained neuroinflammation
 6. Accumulation of ubiquitinated proteins
PD  5. Sustained neuroinflammation  3.  Cholinergic 
dysfunction 6. Accumulation of ubiquitinated proteins
7a.  Intracellular accumulation of α-synuclein 
amyloid-like fibrils (Lewy bodies)
 4.  Cognitive 
changes
 8. Nigral dopamine loss
 9. Movement disorder
MND  5. Sustained neuroinflammation  2.  Increased APP, 
accumulation of 
Aβ and pho-tau
 6. Accumulation of ubiquitinated proteins
 9. Movement disorder  4. Cognitive changes
10. C9ORF72 mutation 7b.  Intracellular 
α-synuclein/SOD1 
co-aggregation 
in amyotrophic 
lateral sclerosis
11.  Intracellular accumulation of aggregated 
proteins (TDP-43, FUS, and SOD1)
Numbers refer to the following references: (1) Hinz and Geschwind (2); Aday and Sze 
(3); (2) Vilemagne et al. (4); Gomez-Pinedo et al. (1); (3) Ballinger et al. (5); Park et al. 
(6); (4) Brandt et al. (7); (5) Chen et al. (8); Amor et al. (9); (6) Atkin and Paulson (10); 
Jansen et al. (11); (7a) Uchihara and Giasson (12); (7b) Helferich et al. (13); (8) Kalia 
and Lang (14); (9) Brandt et al. (7); (10) Ticozzi et al. (15); (11) Guerrero et al. (16).
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neurodegenerative diseases in the hope that it will point them in 
the right direction. After all, these conditions have so far defied 
effective treatment or cure.
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